Filing Flows › Comparisons › EQ vs KYNB
Equillium vs Kyntra Bio: EQ and KYNB compared
Equillium is the larger company: $4.4M of revenue in its latest quarter (Q4 2024) against $3.7M for Kyntra Bio (Q1 2026). Kyntra Bio is growing faster (+36% against -52% a year earlier). Equillium is more profitable, with an operating margin of -107.0% against -369.7%.
Where the money goes: EQ and KYNB
Equillium (EQ) · Q4 2024
Equillium, Q4 2024: revenue $4.4M (-52% year over year), operating margin -107.0%, net loss $5.8M, operating cash flow −$3.3M. The chart follows the revenue to costs, profit and cash.
Kyntra Bio (KYNB) · Q1 2026
Kyntra Bio, Q1 2026: revenue $3.7M (+36% year over year), operating margin -369.7%, net loss $15.2M, operating cash flow −$13.9M. The chart follows the revenue to costs, profit and cash.
| Equillium (EQ) | Kyntra Bio (KYNB) | |
|---|---|---|
| Latest quarter | Q4 2024 | Q1 2026 |
| Revenue | $4.4M | $3.7M |
| Revenue growth, Y/Y | -52% | +36% |
| Operating margin | -107.0% | -369.7% |
| Net earnings | −$5.8M | −$15.2M |
| Net margin | -131.9% | -406.6% |
| Operating cash flow | −$3.3M | −$13.9M |
Where the revenue comes from
Kyntra Bio
- Drug Product Revenue: $3.5M (93%)
- Development and Other Revenue: $246K (7%)
Questions
Which is bigger, Equillium or Kyntra Bio?
Equillium is the larger company: $4.4M of revenue in its latest quarter (Q4 2024) against $3.7M for Kyntra Bio (Q1 2026).
Is Equillium or Kyntra Bio growing faster?
Kyntra Bio is growing faster (+36% against -52% a year earlier).
Which is more profitable, Equillium or Kyntra Bio?
Equillium is more profitable, with an operating margin of -107.0% against -369.7%.
More: Equillium earnings · how Equillium makes money · Kyntra Bio earnings · how Kyntra Bio makes money
From the companies' latest 10-Q, 10-K or earnings release (10-K filed Mar 27, 2025; 10-Q filed May 12, 2026). Fiscal quarters can end on different dates. Not investment advice.